fig9

Figure 9. Immune landscape of MOMLS. (A-D) TIDE immune therapy analysis for epithelial convolution cells; (E) Differences in RMS after 6 months and one year of treatment between high and low MOMLS score groups; (F) LTS differences after 3 months of treatment between high and low MOMLS score groups. MOMLS: Multi-omics-driven machine learning signature; TIDE: tumor immune dysfunction and exclusion; RMS: restricted mean survival time; LTS: long-term survival. ^*P < 0.05; ^**P < 0.01; ^***P < 0.001; ^****P < 0.0001.